BRSR Report of Novartis India Limited for FY 2025-26

Novartis India Limited September 02, 2026 The Secretary BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Scrip Code: 500672 Sub.: Business Responsibility and Sustainability Report for the Financial Year 2025-26 Dear Sir/ Madam, Pursuant to Regulation 34(2)(f) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), please find enclosed the Business Responsibility and Sustainability Report (“BRSR”) of the Company for the financial year ended March 31, 2026, describing the initiatives taken by the Company from an Environmental, Social and Governance perspective. The BRSR forming part of the Annual Report of the Company for F.Y 2025-26 can be accessed on the website of Company at the given link: - https://nilpharma.co.in/annual-general-meeting/ This is for your information and records. You are requested to take the above information on record. Thanking you Yours sincerely, For Novartis India Limited Chandni Maru Company Secretary and Compliance Officer M.No - ACS 60291 Encl.: as above Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@nilpharma.co.in | Website: www.nilpharma.co.in Business Responsibility and Sustainability Reporting About this Report This Business Responsibility and Sustainability Report (BRSR) aims to disclose our performance against the nine principles of the ‘National Guidelines on Responsible Business Conduct’ (NGBRC). The BRSR is designed to help the investors and other stakeholders understand how the business practices are adopted by Novartis India Limited in relation to the environment, people and society. Each principle of the BRSR is further divided into Essential Indicators and Leadership Indicators. Essential Indicators must be reported on a mandatory basis, while the reporting of Leadership Indicators is voluntary. As this is our fourth year, we have disclosed all Essential Indicators and opted for certain Leadership Indicators. As Novartis India Limited is a trading entity, certain indicators do not apply to the company, due to the nature of its operations. Therefore, we have identified and disclosed as “not applicable.” The members are informed that certain disclosures are aligned with applicable policies of its promoter, Novartis AG. Accordingly, the BRSR for the period ended March 31, 2026 has been prepared with reference to these policies and therefore contains certain cross-references to the promoter. SECTION A: GENERAL DISCLOSURES I. Details of the listed entity 1. Corporate Identity Number (CIN) of the L24200MH1947PLC006104 Listed Entity 2. Name of the Listed Entity Novartis India Limited 3. Year of Incorporation 1947 4. Registered office address Inspire BKC, 7th Floor, Bandra Kurla Complex, Bandra (East), Mumbai, Maharashtra, India, 400051. 5. Corporate Address Inspire BKC, 7th Floor Bandra Kurla Complex, Bandra (East) Mumbai - 400051 6. Email investor.relations@nilpharma.co.in 7. Telephone +91 22 50243000 8. Website https://nilpharma.co.in/ 9. Financial year for which reporting is being 1st April 2025 – 31st March 2026 done 10. Name of the Stock Exchange(s) where BSE Limited shares are listed 11. Paid-up Capital ` 123,453,985 12. Name and contact details (telephone, Ms. Chandni Maru email address) of the person who may be Company Secretary and Compliance contacted in case of any queries on the Officer BRSR report: Email ID: investor.relations@nilpharma.co.in Contact No: +91 22 50243000 13. Reporting Boundary - Are the disclosures under this report made on a standalone basis (i.e. only for the entity) or on a consolidated basis (i.e. for the entity and Standalone all the entities which form a part of its consolidated financial statements, taken together). 14. Name of assurance provider Not Applicable 15. Type of assurance obtained Not Applicable NOVARTIS INDIA LIMITED Annual Report 2025 – 26 105 II. Products/services 16. Details of business activities (accounting for 90% of the turnover): S. No. Description of Main Activity Description of Business % of Turnover of the entity Activity 1. Pharmaceuticals Trading 100% 17. Products/Services sold by the entity (accounting for 90% of the entity’s Turnover): S. No. Product/Service NIC Code % of total Turnover contributed 1. Wholesale of pharmaceutical and 46497 100% medical goods III. Operations 18. Number of locations where plants and/or operations/offices of the entity are situated: Location Number of plants Number of offices Total National — 7 7 International — — — Note: The Company is engaged in trading and distribution of pharmaceutical products and does not have any manufacturing facilities. The operational footprint comprises one corporate office and six warehousing locations across India. Note: The Company has operations across 22 states in India, with warehouses located in Mumbai, Haryana, Kolkata, Chennai and Ghaziabad. Its corporate office is situated in Mumbai. 19. Markets served by the entity: a. Number of locations Locations Number National (No. of States) 22* International (No. of Countries) — *The number is based on GST registrations. b. What is the contribution of exports as a percentage of the total turnover of the entity? Contribution of exports is NIL. c. A brief on types of customers Our customer base includes distributors, private hospitals and Government Institutions to whom we sell our products. IV. Employees 20. Details as at the end of the Financial Year: a. Employees and workers (including differently abled): Male Female Particulars Total A No. B/A No. C/A B % C % Employees 1. Permanent (D) 57 48 84% 9 16% 2. Other than Permanent (E) 2 0 0% 2 100% 3. Total employees (D+E) 59 48 81% 11 19% NOVARTIS INDIA LIMITED 106 Annual Report 2025 – 26 Male Female Particulars Total A No. B/A No. C/A B % C % Workers 4. Permanent (F) — — — — — 5. Other than Permanent (G) — — — — — 6. Total workers (F+G) — — — — — b. Differently abled Employees and workers: Male Female Particulars Total A No. B/A No. C/A B % C % Differently abled Employees 1. Permanent (D) 0 0 0 0 0 2. Other than Permanent (E) 0 0 0 0 0 3. Total differently abled 0 0 0 0 0 employees (D+E) Differently Abled Workers 4. Permanent (F) 0 0 0 0 0 5. Other than permanent (G) 0 0 0 0 0 6. Total differently abled workers 0 0 0 0 0 (F+G) 21. Participation/Inclusion/Representation of women No. and percentage of Females Total (A) No. (B) % (B/A) Board of Directors 6 3 50.00% Key Management Personnel 3 2 66.66% 22. T urnover rate for permanent employees and workers: (Disclose trends for the past 3 years) FY Apr 2023 - Mar 2024 FY Apr 2025 - Mar 2026 FY Apr 2024- Mar 2025 (Turnover rate in (Turnover rate in Current (Turnover rate in year prior to previous Financial Year) previous Financial Year) Financial Year) Male Female Total Male Female Total Male Female Total Permanent Employees 0% 0% 0% 7% 0% 7% 11% 10% 11% Permanent Workers — — — — — — — — — Note: There have been no separation cases for the year 2025-26. IV. Holding, Subsidiary and Associate Companies (including joint ventures) 23. (a) Names of holding/ subsidiary/ associate companies/ joint ventures Does the entity indicated Name of the holding/ Indicate whether % of shares at column A, participate S. subsidiary/ associate holding/ Subsidiary/ held by in the Business No. companies/ joint ventures Associate/ Joint listed entity Responsibility initiatives of (A) Venture the listed entity? (Yes/No) 1. Novartis AG Holding 70.68% No * Novartis AG, being a foreign entity is governed by laws of host country. However, Novartis AG has aligned its practices to global sustainability standards NOVARTIS INDIA LIMITED Annual Report 2025 – 26 107 V. CSR Details 24. (i) Whether CSR is applicable as per section 135 of Companies Act, 2013: (Yes/No) (ii) Turnover (in `) - ` 3,543.4 Mn (iii) Net worth (in `) - ` 8,178.3 Mn VI [Showing first 8,000 characters — download PDF for full document]